180 Life Sciences Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 180 Life Sciences Corp.
After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.
Celltrion has struck a deal with 180 Life Sciences to supply anti-TNF products to support the company’s work in pursuing new indications for off-patent biologics.
- Large Molecule
- Other Names / Subsidiaries
- 180 Therapeutics LP